Search research articles
Contact Us
Filters
Showing results (41-50 of 48) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 48 results.
Cancer
|
March 13, 2016
Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study
Didier Meulendijks, Jan Willem B de Groot, Maartje Los, et al.
The Lancet. Oncology
|
November 26, 2015
Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data
Didier Meulendijks, Linda M Henricks, Gabe S Sonke, et al.
Clinical Pharmacology and Therapeutics
|
April 9, 2022
Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study
Mirjam de With, Jonathan Knikman, Femke M de Man, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 28, 2023
Survival of Patients With Cancer With <i>DPYD</i> Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy-A Matched-Pair Analysis
Jonathan E Knikman, Tycho A Wilting, Marta Lopez-Yurda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 11, 2017
Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity
Didier Meulendijks, Wolfgang Jacob, Emile E Voest, et al.
British Journal of Cancer
|
January 15, 2024
Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis
Gwénaël Le Teuff, Nathalie Cozic, Jean-Christophe Boyer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 14, 2018
A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy
Linda M Henricks, Carin A T C Lunenburg, Femke M de Man, et al.
The Lancet. Oncology
|
October 24, 2018
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
Linda M Henricks, Carin A T C Lunenburg, Femke M de Man, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 48) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 48 results.
Cancer
|
March 13, 2016
Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study
Didier Meulendijks, Jan Willem B de Groot, Maartje Los, et al.
The Lancet. Oncology
|
November 26, 2015
Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data
Didier Meulendijks, Linda M Henricks, Gabe S Sonke, et al.
Clinical Pharmacology and Therapeutics
|
April 9, 2022
Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study
Mirjam de With, Jonathan Knikman, Femke M de Man, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 28, 2023
Survival of Patients With Cancer With <i>DPYD</i> Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy-A Matched-Pair Analysis
Jonathan E Knikman, Tycho A Wilting, Marta Lopez-Yurda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 11, 2017
Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity
Didier Meulendijks, Wolfgang Jacob, Emile E Voest, et al.
British Journal of Cancer
|
January 15, 2024
Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis
Gwénaël Le Teuff, Nathalie Cozic, Jean-Christophe Boyer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 14, 2018
A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy
Linda M Henricks, Carin A T C Lunenburg, Femke M de Man, et al.
The Lancet. Oncology
|
October 24, 2018
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
Linda M Henricks, Carin A T C Lunenburg, Femke M de Man, et al.
Page
of 5